Form 4: Organogenesis Director Sells 300,000 Shares

Glenn H. Nussdorf, a Director and 10% owner of Organogenesis Holdings Inc., sold 300,000 shares of Class A Common Stock over three days in late November 2025.

Summary

• Glenn H. Nussdorf, a Director and 10% owner of Organogenesis Holdings Inc. (ORGO), sold a total of 300,000 shares of Class A Common Stock.
• The sales occurred on November 24, 25, and 26, 2025.
• On November 24, 2025, 100,000 shares were sold at a weighted-average price of $5.34 per share, with prices ranging from $5.30 to $5.40.
• On November 25, 2025, 12,043 shares were sold at a price of $5.30 per share.
• On November 26, 2025, 187,957 shares were sold at a weighted-average price of $5.29 per share, with prices ranging from $5.25 to $5.39.
• Following these transactions, Mr. Nussdorf directly beneficially owns 2,765,591 shares and indirectly owns 9,182,969 shares through various trusts.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a director and 10% owner. While the 10b5-1 plan mitigates some of the immediate negative implications, the volume of shares sold still suggests a potential lack of strong conviction or a desire for diversification at current price levels.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not necessarily a reaction to recent negative company developments.

Negatives

• A Director and 10% owner sold a significant number of shares (300,000 shares).
• Insider selling, especially by a large shareholder and director, can be perceived negatively by the market, suggesting a lack of confidence or a desire to diversify holdings.

Risks

• Potential negative market perception due to significant insider selling by a director and 10% owner.
• The sale could put downward pressure on the stock price if investors interpret it as a lack of confidence.

Industry Context

This filing is specific to an insider transaction and does not provide information directly related to broader industry trends or competitor performance. However, significant insider selling in the biotechnology or medical device sector can sometimes signal a shift in insider confidence, which might be observed across the industry if there are broader headwinds.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.
• Employees: No direct impact mentioned, but a decline in stock price could affect employee stock options or morale.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to Organogenesis, any security holder, or the SEC staff.

Key Dates

Recommendation

While the sale by a director and 10% owner of 300,000 shares is a notable event, the fact that it was executed under a Rule 10b5-1 plan suggests it was pre-scheduled and not necessarily a reaction to new, undisclosed negative information. However, the significant volume of shares sold by a key insider warrants caution. Investors should 'hold' and monitor future insider activity, company performance, and market sentiment before making further investment decisions. This sale, while planned, still removes a significant block of shares from a major insider's direct holdings, which could be interpreted as a lack of strong conviction at current valuations.

Keywords

Organogenesis Holdings Inc., ORGO, insider trading, Form 4, Glenn H. Nussdorf, stock sale, director, 10% owner, beneficial ownership, Class A Common Stock, SEC filing, Rule 10b5-1